Principal investigator or sub-investigator documents the name of adverse event, date of occurrence, intensity, seriousness, study drug adjustment, treatment for the adverse event, outcome, date of outcome, and relationship with the clinical study. For an adverse event which is observed from the initiation of the study drug administration to follow-up examination, the relationship with the study drug is also documented.